Viridian Therapeutics, Inc. VRDN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$104.9M+12.8% | -$120.36M-248% | -$34.6M+65.7% | -$100.74M-15.9% | -$86.91M-9.0% | ||
| $121K+0.8% | $120K+9.1% | $110K-2.7% | $113K-3.4% | $117K-4.9% | ||
| $13.39M+11.7% | $11.99M+6.6% | $11.25M+3.7% | $10.84M+6.1% | $10.22M+13.9% | ||
| $4.63M— | —— | $1.55M-66.6% | $4.63M+162% | $1.77M+145% | ||
| -$23.69M-211% | $21.32M— | —— | —— | -$15.91M-247% | ||
| $2.33M— | —— | -$3.37M+35.1% | -$5.19M-1,722% | -$285K-104% | ||
| -$169K+99.8% | -$70.16M-200% | $70M+1,166,767% | -$6K-200% | $6K+101% | ||
| -$119.65M-404% | -$23.75M+71.9% | -$84.61M-12.3% | -$75.37M+18.7% | -$92.65M-26.3% | ||
| $23K-90.4% | $240K+89.0% | $127K+202% | $42K-51.2% | $86K-24.6% | ||
| $91.32M-79.2% | $438.19M+3,011% | $14.09M-74.7% | $55.76M-21.7% | $71.24M-60.8% | ||
| $168.6M+70.3% | $99.01M-29.4% | $140.29M+6.7% | $131.52M-23.3% | $171.39M+44.1% | ||
| $77.26M+123% | -$339.42M-369% | $126.08M+66.5% | $75.72M-24.3% | $100.06M+259% | ||
| $0-100% | $48.24M+307% | $11.84M— | $0-100% | $4.94M-85.3% | ||
| —— | $119.5K0.0% | $119.5K0.0% | $119.5K0.0% | $119.5K— | ||
| $6.36M-98.4% | $405.91M+3,639% | $10.86M+1,321% | $764K-91.7% | $9.21M-74.1% | ||
| -$36.04M-184% | $42.74M-18.3% | $52.32M+4,618% | $1.11M-93.3% | $16.62M+117% | ||
| $1.12M+42.0% | $788K+72.4% | $457K0.0% | $457K+2.0% | $448K-1.1% | ||
| $1.86M+5.9% | $1.75M+54.7% | $1.13M-27.0% | $1.55M-33.1% | $2.32M-27.7% | ||
| $7.53M— | —— | —— | —— | $0— | ||
| —— | $437.75K0.0% | $437.75K0.0% | $437.75K0.0% | $437.75K— | ||
| $2.33M— | —— | -$3.37M+35.1% | -$5.19M-1,722% | -$285K-104% | ||
| -$169K— | —— | —— | —— | $6K+101% | ||
| $2.34M+3.8% | $2.26M— | —— | —— | $103K+74.6% | ||
| $168.6M+70.3% | $99.01M-29.4% | $140.29M+6.7% | $131.52M-23.3% | $171.39M+44.1% | ||
| —— | $1.25M0.0% | $1.25M0.0% | $1.25M0.0% | $1.25M— | ||
| —— | $119.5K0.0% | $119.5K0.0% | $119.5K0.0% | $119.5K— | ||
| $0— | —— | —— | —— | $207K— | ||
| —— | $13.75M0.0% | $13.75M0.0% | $13.75M0.0% | $13.75M— | ||
| $0— | —— | $559K— | —— | $561K+56,000% | ||
| $0— | —— | —— | —— | $1.62M— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$119.68M-399% | -$23.99M+71.7% | -$84.74M-12.4% | -$75.42M+18.7% | -$92.74M-26.3% | ||
| -$119.68M-399% | -$23.99M+71.7% | -$84.74M-12.4% | -$75.42M+18.7% | -$92.74M-26.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viridian Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.